NCT07051928Not yet recruiting
Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.
A Prospective, Observational, Single Arm, Multi-site, Pilot Study of Atezolizumab in Non-oncogene Addicted Advanced Nsclc Patients With Pd-l1 Tps ≥ 50%, With Longitudinal Assessment of C-FLIP Expression of Monocytic Myeloid-derived Suppressor Cells
Source: ClinicalTrials.gov · Last updated 9 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prospective, observational, multi-site, single arm, exploratory pilot study, designed to prospectively assess the relationship between basal c-FLIP expression in M-MDSCs with clinical outcomes in patients treated with anti-PD-L1 monotherapy in a 1L mNSCLC setting, as well as evaluate changes in c-FLIP during treatment and correlate those changes with clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 107 (estimated)
- First submitted
- 26 Jun 2025
- Start date
- Jul 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Lung cancer
- NCT number
- NCT07051928
What you commit to
- Study type: Observational
- Planned participants: 107
- From Jul 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ineligibility to receive first line immunotherapy treatment
- Patients with driver mutations amenable to molecular targeted therapies in I-line according to the indications of the AIFA
Who the study is looking for
- Age ≥ 18 years at time of signing Informed Consent Form
- ECOG Performance Status of 0-2
- Advanced/metastatic NSCLC without prior treatment in the metastatic setting
- Tumor PD-L1 expression with a TPS ≥ 50%, documented through local testing
- Measurable disease per RECIST v1.1
- Adequate hematologic and end-organ function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.